20/20 GeneSystems' Unattributed - III Round

20/20 GeneSystems raised a round of funding on August 18, 2014. Investors include Bao Hao Investment Management Co..

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a propriet…

Articles about 20/20 GeneSystems' Unattributed - III Round: